Visual acuity outcomes after cataract surgery in type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study

Type 2 DiabetesDiabetic ComplicationsGlycemic Control

Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.

Diabetes Care.

Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group

doi: 10.2337/dc16-0024.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

N Engl J Med.

Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S

doi: 10.1056/NEJMoa1800256.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

Diabetes Care.

Kaul S

doi: 10.2337/

Diabetes - GeneralType 2 Diabetes

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial

JAMA Cardiol.

Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E

doi: 10.1001/

COMMENTED

Glycemic Control

Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study

Diabetes Care.

Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG

doi: 10.2337/dc18-0287.

COMMENTED

Type 2 DiabetesObesity and Bariatric Surgery

Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity

JAMA.

Aminian A, Zajichek A, Arterburn DE, Wolski KE, Brethauer SA, Schauer PR, Kattan MW, Nissen SE

doi: 10.1001/jama.2019.14231.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults

Diabetologia.

Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbæk A

doi: 10.1007/s00125-017-4323-2.

Diabetes - GeneralType 2 Diabetes

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Diabetologia.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B

doi: 10.1007/s00125-018-4644-9.

RECOMMENDED

Type 2 Diabetes

Birth Weight and Risk of Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension in Adults: A Meta-Analysis of 7 646 267 Participants From 135 Studies

J Am Heart Assoc.

Knop MR, Geng TT, Gorny AW, Ding R, Li C, Ley SH, Huang T

doi: 10.1161/JAHA.118.008870.

Related content

Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial

Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study

Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity

Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Birth Weight and Risk of Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension in Adults: A Meta-Analysis of 7 646 267 Participants From 135 Studies